Commentary

‘Miracle cures’ in psychiatry?

Current Psychiatry. 2019 September;18(9):13-16

References

1. Freud S. Cocaine papers. In: Freud S, Byck R. Sigmund Freud collection (Library of Congress). New York, NY: Stonehill; 1975;7.
2. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164(2):201-204.
3. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-1989.
4. Carey B. Fast-acting depression drug, newly approved, could help millions. The New York Times. https://www.nytimes.com/2019/03/05/health/depression-treatment-ketamine-fda.html. Published March 5, 2019. Accessed July 26, 2019.
5. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.
6. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43:55-60.
7. Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2014;7(3):157-164.
8. Simon RI. Clinical psychiatry and the law. 2nd ed. Washington, DC: American Psychiatric Press; 1992.
9. Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455-467.
10. Perrine SA, Sheikh IS, Nwaneshiudu CA, et al. Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. Neuropharmacology. 2008;54(2):355-364.
11. Doroshow DB. Performing a cure for schizophrenia: insulin coma therapy on the wards. J Hist Med Allied Sci. 2007;62(2):213-243.
12. Khan A, Kolts RL, Rapaport MH, et al. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35(5):743-749.
13. Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816-826.
14. Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205-1215.
15. Duman RS, Aghajanian GK, Sanacora G, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(2):238-249.
16. Carhart-Harris RL. How do psychedelics work? Curr Opin Psychiatry. 2019;32(1):16-21.
17. Martins SS, Fenton MC, Keyes KM, et al. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med. 2012;42(6):1261-1272.
18. Thielking M. Ketamine gives hope to patients with severe depression. But some clinics stray from the science and hype its benefits. STAT. https://www.statnews.com/2018/09/24/ketamine-clinics-severe-depression-treatment/. Published September 24, 2018. Accessed July 26, 2019.
19. Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-1429.

‘Miracle cures’ in psychiatry?

References

Tempering excitement with caution

Pages

Recommended Reading